ACAD
38.03
-0.64
-1.66%
AEMD
0.196
-0.01
-4.6341%
APRI
1.77
-0.01
-0.56%
ARNA
4.64
-0.02
-0.43%
ATEC
1.43
+0.02
+1.42%
CNAT
6.43
-0.22
-3.31%
CRXM
0.35
+0.06
+20.69%
CYTX
1.11
-0.03
-2.63%
DXCM
67.4
-0.53
-0.78%
GNMK
10.86
-2.02
-15.68%
HALO
15.3
-0.22
-1.42%
ILMN
191.16
-1.86
-0.96%
INNV
0.15
0.00
0.00%
INO
10.04
-0.28
-2.76%
ISCO
0.057
-0.001
-0.870%
ISIS
65.33
-0.98
-1.48%
LGND
85.85
-1
-1.15%
LPTN
2.26
+0.03
+1.35%
MBVX
3.55
+0.05
+1.43%
MEIP
2.12
0.00
0.00%
MNOV
4.45
-0.51
-10.28%
MRTX
27.59
-0.21
-0.76%
MSTX
0.472
-0.009
-1.871%
NBIX
42.49
-1.12
-2.57%
NUVA
41.55
-1.18
-2.76%
ONCS
0.31
0.00
-1.59%
ONVO
4.56
-0.16
-3.39%
OREX
7.54
-0.26
-3.33%
OTIC
31.86
-0.52
-1.61%
QDEL
23.7
-0.9
-3.66%
RCPT
167.38
-0.59
-0.35%
RGLS
17.3
+0.12
+0.70%
RMD
71.88
-0.37
-0.51%
SCIE
0.025
-0.002
-7.063%
SPHS
0.81
-0.05
-5.81%
SRNE
11.31
+0.16
+1.43%
TROV
8.53
+1.43
+20.14%
VICL
0.94
-0.01
-1.05%
VOLC
17.99
0.00
0.00%
ZGNX
1.58
-0.02
-1.25%
ACAD
38.03
-0.64
-1.66%
AEMD
0.196
-0.01
-4.6341%
APRI
1.77
-0.01
-0.56%
ARNA
4.64
-0.02
-0.43%
ATEC
1.43
+0.02
+1.42%
CNAT
6.43
-0.22
-3.31%
CRXM
0.35
+0.06
+20.69%
CYTX
1.11
-0.03
-2.63%
DXCM
67.4
-0.53
-0.78%
GNMK
10.86
-2.02
-15.68%
HALO
15.3
-0.22
-1.42%
ILMN
191.16
-1.86
-0.96%
INNV
0.15
0.00
0.00%
INO
10.04
-0.28
-2.76%
ISCO
0.057
-0.001
-0.870%
ISIS
65.33
-0.98
-1.48%
LGND
85.85
-1
-1.15%
LPTN
2.26
+0.03
+1.35%
MBVX
3.55
+0.05
+1.43%
MEIP
2.12
0.00
0.00%
MNOV
4.45
-0.51
-10.28%
MRTX
27.59
-0.21
-0.76%
MSTX
0.472
-0.009
-1.871%
NBIX
42.49
-1.12
-2.57%
NUVA
41.55
-1.18
-2.76%
ONCS
0.31
0.00
-1.59%
ONVO
4.56
-0.16
-3.39%
OREX
7.54
-0.26
-3.33%
OTIC
31.86
-0.52
-1.61%
QDEL
23.7
-0.9
-3.66%
RCPT
167.38
-0.59
-0.35%
RGLS
17.3
+0.12
+0.70%
RMD
71.88
-0.37
-0.51%
SCIE
0.025
-0.002
-7.063%
SPHS
0.81
-0.05
-5.81%
SRNE
11.31
+0.16
+1.43%
TROV
8.53
+1.43
+20.14%
VICL
0.94
-0.01
-1.05%
VOLC
17.99
0.00
0.00%
ZGNX
1.58
-0.02
-1.25%
Home » Hugo Villar, Ph.D., MBA-Bio

Hugo Villar, Ph.D., MBA-Bio

Hugo O. Villar Ph.D., MBA is director for Science and Technology programs at UC San Diego Extension. He is also President of Altoris, Inc. a San Diego based specializing in information management for the biotech and pharmaceutical industries and providing consulting on discovery technologies. He was Vice President for Chemoproteomics at Triad Therapeutics and Vice President of Discovery Technologies at Telik, Inc. His work resulted in over 80 publications and 18 patents on the development of technologies for drug discovery. He has a Ph.D. in Chemistry and an MBA with a concentration in Pharmaceuticals and Helathcare.